Latest Ratios: P/E Ratio -3.9x · EV/EBITDA N/A · ROE -612.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $186M | $234M | $206M | $238M | $291M | $351M | $311M | $284M | $394M | $387M | $314M |
| Enterprise Value | $309M | $357M | $331M | $331M | $538M | $565M | $532M | $435M | $464M | $436M | $366M |
| P/E Ratio → | -3.91 | — | 17.03 | — | — | — | — | 133.69 | 15.84 | 36.84 | — |
| P/S Ratio | 1.44 | 1.82 | 1.61 | 2.30 | 2.61 | 3.48 | 1.94 | 0.51 | 0.75 | 0.73 | 0.58 |
| P/B Ratio | 129.27 | 175.14 | 18.21 | — | 3.31 | 1.73 | 1.35 | 1.05 | 1.56 | 1.70 | 1.48 |
| P/FCF | — | — | — | — | — | — | — | — | — | 57.48 | — |
| P/OCF | — | — | 801.63 | — | — | 21.29 | — | 17.71 | 19.90 | 13.20 | 14.43 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.77 | 2.58 | 3.21 | 4.83 | 5.60 | 3.32 | 0.78 | 0.88 | 0.82 | 0.68 |
| EV / EBITDA | — | — | — | — | 85.75 | 51.19 | — | 66.04 | 19.47 | 16.64 | — |
| EV / EBIT | — | — | 12.00 | — | — | — | — | 49.07 | 34.12 | 27.23 | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | 64.69 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.3% | 31.3% | 32.6% | 27.1% | 35.1% | 38.6% | 24.6% | 14.5% | 14.9% | 15.6% | 13.1% |
| Operating Margin | -13.4% | -13.4% | -6.9% | -21.1% | -10.6% | -8.7% | -16.2% | -1.4% | 2.3% | 2.9% | -3.7% |
| Net Profit Margin | -30.0% | -30.0% | 9.4% | -96.4% | -104.9% | -32.0% | -23.9% | 0.4% | 4.7% | 2.0% | -2.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -612.1% | -612.1% | 339.1% | -238.2% | -80.3% | -14.9% | -15.2% | 0.8% | 10.3% | 4.8% | -5.4% |
| ROA | -15.7% | -15.7% | 4.7% | -37.7% | -30.0% | -6.2% | -7.2% | 0.5% | 6.5% | 3.0% | -3.4% |
| ROIC | -9.9% | -9.9% | -5.9% | -7.7% | -2.4% | -1.5% | -4.4% | -1.6% | 3.0% | 4.3% | -5.8% |
| ROCE | -8.1% | -8.1% | -4.1% | -14.0% | -4.7% | -2.3% | -6.8% | -2.3% | 3.8% | 5.2% | -6.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 97.92 | 97.92 | 11.81 | — | 2.82 | 1.06 | 0.96 | 0.56 | 0.29 | 0.24 | 0.29 |
| Debt / EBITDA | — | — | — | — | 39.52 | 19.55 | — | 23.14 | 3.06 | 2.06 | — |
| Net Debt / Equity | — | 91.74 | 11.06 | — | 2.81 | 1.06 | 0.96 | 0.56 | 0.28 | 0.21 | 0.25 |
| Net Debt / EBITDA | — | — | — | — | 39.36 | 19.44 | — | 22.98 | 2.94 | 1.85 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | 7.21 | — |
| Interest Coverage | -0.77 | -0.77 | 1.53 | -2.63 | -0.34 | -2.33 | -5.60 | 1.70 | 6.97 | 8.76 | -8.49 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.84 | 2.84 | 2.08 | 2.39 | 0.66 | 1.46 | 0.96 | 0.97 | 1.10 | 1.58 | 1.53 |
| Quick Ratio | 1.77 | 1.77 | 1.06 | 1.35 | 0.46 | 0.84 | 0.55 | 0.58 | 0.74 | 1.09 | 1.08 |
| Cash Ratio | 0.27 | 0.27 | 0.22 | 0.49 | 0.01 | 0.01 | 0.00 | 0.01 | 0.03 | 0.11 | 0.18 |
| Asset Turnover | — | 0.54 | 0.51 | 0.41 | 0.41 | 0.20 | 0.30 | 1.07 | 1.30 | 1.49 | 1.58 |
| Inventory Turnover | 2.74 | 2.74 | 2.16 | 1.84 | 2.01 | 0.98 | 1.82 | 8.80 | 14.01 | 17.76 | 18.41 |
| Days Sales Outstanding | — | 123.68 | 88.65 | 102.58 | 125.68 | 149.91 | 173.77 | 45.54 | 37.51 | 31.48 | 31.30 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 5.9% | — | — | — | — | 0.7% | 6.3% | 2.7% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | 1.7% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $35M | $37M | $30M | $29M | $29M | $29M | $29M | $28M | $28M | $27M |
Liquidity and operational insolvency
As reported in recent financial filings, LFCR trades at a price-to-sales ratio of 1.50, a multiple that appears to reflect significant market skepticism regarding the company's ability to successfully pivot toward a pure-play CDMO model while burdened by legacy food assets and persistent net losses.
The negative P/E ratio of -4.07 underscores the absence of current earnings, making traditional valuation metrics largely irrelevant for assessing the company's intrinsic value. Investors should monitor whether the market continues to apply a conglomerate discount or if the potential divestiture of the food segment acts as a catalyst for a valuation re-rating.
Based on the provided quarterly data, LFCR's ROIC has trended into negative territory, reaching -2.3% in 2026Q3, which suggests that the company is currently destroying shareholder value rather than compounding it through its capital-intensive aseptic manufacturing operations.
The inability to generate positive returns on invested capital appears to stem from low capacity utilization and the high fixed-cost burden of maintaining FDA-validated facilities. This trend warrants further investigation into whether the company can achieve the necessary scale to turn ROIC positive once the strategic transition is complete.
According to recent financial statements, the cash conversion cycle has expanded to 225 days in 2026Q3, a significant deterioration that highlights the company's struggle to manage inventory and collect receivables efficiently during its ongoing corporate transformation.
The elevated days sales outstanding of 118 days suggests potential challenges in customer payment terms or collection processes, which further strains the company's limited liquidity. Investors should monitor whether these efficiency metrics improve as the company sheds its legacy food business and focuses on the more predictable CDMO service model.
As indicated by the reported figures, LFCR's debt-to-equity ratio reached an extreme 97.92 in 2025Q4, signaling a highly leveraged balance sheet that leaves the company with minimal margin for error in its operational execution or debt service obligations.
The erratic interest coverage ratios, including negative values in recent periods, suggest that the company may be struggling to cover its financing costs from core operating cash flows. This level of leverage appears to be a primary risk factor that could necessitate dilutive equity financing if operational performance does not improve rapidly.
The price-to-book ratio of 134.74 is a highly misleading metric for LFCR, as it obscures the reality that the company's book value has been severely eroded by accumulated losses and restructuring charges rather than reflecting a premium valuation of its underlying assets.
Investors should instead focus on the enterprise value relative to the potential capacity of the CDMO segment, as the book value is currently distorted by the legacy food assets and intangible write-downs. Relying on P/B in this context may lead to a false sense of asset backing that does not exist in a liquidation or distress scenario.
Includes 30+ ratios · 29 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LFCR stock.
Lifecore Biomedical, Inc.'s current P/E ratio is -3.9x. The historical average is 33.2x.
Lifecore Biomedical, Inc.'s return on equity (ROE) is -612.1%. The historical average is 0.6%.
Based on historical data, Lifecore Biomedical, Inc. is trading at a P/E of -3.9x. Compare with industry peers and growth rates for a complete picture.
Lifecore Biomedical, Inc. has 31.3% gross margin and -13.4% operating margin.